Nasus Pharma (NSRX) Total Debt (2024)

Nasus Pharma (NSRX) reported Total Debt of $1.8 million for Q4 2024.

Nasus Pharma (NSRX) Total Debt (2024) Analysis & Trends

Nasus Pharma has reported Total Debt for 1 years, with the latest figure at $1.8 million in Q4 2024.

For the quarter ending Q4 2024, Total Debt changed N/A year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2024 stood at $1.8 million (changed N/A YoY), and the FY2024 full-year result was $1.8 million, changed N/A from the prior year.
Total Debt for Q4 2024 stood at $1.8 million.
The five-year high for Total Debt was $1.8 million in Q4 2024, with the low at $1.8 million in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-18.89 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	43.37 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	54.99 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	64.53 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	49.12 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	57.32 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	22.17 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	64.46 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	44.46 Bn
10	Nasus Pharma	24.83 Mn	20.55 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	1.80 Mn